Recently, an aberrant overexpression of BTK is also found in breast cancer, ovarian cancer and colorectal cancer (Lavitrano et al., 2020), (Molina-Cerrillo et al., 2017), and the suppression of BTK by specific inhibitors or RNA interference has shown an enhanced chemosensitivity of cancer cells and the substantial inhibition of tumor growth (Yeh et al., 2021), (Chen et al., 2021a). The gene discussed is BTK; the disease is ovarian cancer.